Aktueller Stand der neoadjuvanten Therapie bei Weichteilsarkomen

The treatment of soft tissue sarcoma is clinically challenging. Referral to an experienced center with an interdisciplinary team is strongly recommended. Neoadjuvant therapy, including irradiation and chemotherapy, has been applied to improve local control rates, eradicate micrometastases and assess...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lehnhardt, Marcus (VerfasserIn) , Schmitt, Thomas (VerfasserIn) , Bischof, Marc (VerfasserIn) , Daigeler, Adrien (VerfasserIn) , Egerer, Gerlinde (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Deutsch
Veröffentlicht: 19. Oktober 2011
In: Der Chirurg
Year: 2011, Jahrgang: 82, Heft: 11, Pages: 995-1000
ISSN:1433-0385
DOI:10.1007/s00104-011-2132-6
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00104-011-2132-6
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s00104-011-2132-6
Volltext
Verfasserangaben:M. Lehnhardt, T. Schmitt, M. Bischof, A. Daigeler, G. Egerer
Beschreibung
Zusammenfassung:The treatment of soft tissue sarcoma is clinically challenging. Referral to an experienced center with an interdisciplinary team is strongly recommended. Neoadjuvant therapy, including irradiation and chemotherapy, has been applied to improve local control rates, eradicate micrometastases and assess chemosensitivity. However, the role of neoadjuvant therapy remains controversial, especially for systemic therapy, as the only available randomized trial failed to prove a benefit for survival. Nevertheless, on the basis of the current body of literature, neoadjuvant therapy can be considered on an individual basis for patients with high-risk tumors. Whenever possible, patients should be included in a clinical trial.
Beschreibung:Gesehen am 10.08.2022
Beschreibung:Online Resource
ISSN:1433-0385
DOI:10.1007/s00104-011-2132-6